Spatial Analysis of up to 30 Proteins on FFPE Tumor Biopsies May Inform Patient Treatment Decisions
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005550/en/
GeoMx Digital Spatial Profiler. (Photo: Business Wire)
Under the collaboration, pathologists at OHSU intend to design a new GeoMx protein assay with up to 30 targets, including existing breast cancer diagnostic markers and novel biomarker candidates. The GeoMx protein assays will be analytically and clinically validated by OHSU for potential use as laboratory developed tests. The development of a high-content spatial protein test using GeoMx may present new opportunities to enhance pathology insights for improved patient outcomes.
“We believe that the GeoMx DSP is the only spatial platform with the potential to serve the needs of discovery research, translational research, and clinical diagnostics,” said
“The development of novel GeoMx DSP protein assays expands the potential applications of spatial biology with the goal of providing better patient care through advanced molecular testing,” said
To learn more about NanoString’s GeoMx Digital Spatial Profiler, please visit https://www.nanostring.com/products/geomx-digital-spatial-profiler/geomx-dsp.
For more information, please visit www.nanostring.com.
Vice President, Investor Relations & Corporate Communications